PIK3CA and thymoma: Likewise, a clinical trial with buparlisib, a pan-PI3K inhibitor, has shown modest activity in B2 and B3 thymomas, with more than half of patients requiring early discontinuation due to dermatologic and pulmonary toxicity, advising extreme caution when approaching the use of PI3K inhibitors in TETs [132].